tiprankstipranks
Immunicum AB (DE:1YG0)
FRANKFURT:1YG0
Germany Market
Holding DE:1YG0?
Track your performance easily

Immunicum AB (1YG0) Stock Forecast & Price Target

1 Followers
See the Price Targets and Ratings of:

1YG0 Analyst Ratings

Currently, no data available
Based on 0 analysts giving stock ratings to
Immunicum
AB
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

1YG0 Stock 12 Month Forecast

There Are No Analyst Ratings for DE:1YG0 In The Last 3 Months.
Highest Price TargetAverage Price TargetLowest Price Target
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

1YG0 Financial Forecast

1YG0 Earnings Forecast

Next quarter’s earnings estimate for 1YG0 is -€0.06 with a range of -€0.06 to -€0.05. The previous quarter’s EPS was -€0.04. 1YG0 beat its EPS estimate 66.67% of the time in the past 12 months, while its overall industry beat the EPS estimate 59.62% of the time in the same period. In the last calendar year 1YG0 has Outperformed its overall industry.
Next quarter’s earnings estimate for 1YG0 is -€0.06 with a range of -€0.06 to -€0.05. The previous quarter’s EPS was -€0.04. 1YG0 beat its EPS estimate 66.67% of the time in the past 12 months, while its overall industry beat the EPS estimate 59.62% of the time in the same period. In the last calendar year 1YG0 has Outperformed its overall industry.

1YG0 Sales Forecast

Next quarter’s sales forecast for 1YG0 is €0.00 with a range of €0.00 to €0.00. The previous quarter’s sales results were €0.00. 1YG0 beat its sales estimates 0.00% of the time in past 12 months, while its overall industry beat sales estimates 48.39% of the time in the same period. In the last calendar year 1YG0 has Underperformed its overall industry.
Next quarter’s sales forecast for 1YG0 is €0.00 with a range of €0.00 to €0.00. The previous quarter’s sales results were €0.00. 1YG0 beat its sales estimates 0.00% of the time in past 12 months, while its overall industry beat sales estimates 48.39% of the time in the same period. In the last calendar year 1YG0 has Underperformed its overall industry.

1YG0 Analyst Recommendation Trends

Currently, no data available
Please return soon. This page is being updated.
Each month's total comprises the sum of three months' worth of ratings.
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

1YG0 Stock Forecast FAQ

What is DE:1YG0’s average 12-month price target, according to analysts?
Currently, no data Available
What is DE:1YG0’s upside potential, based on the analysts’ average price target?
Currently there's no upside potential for DE:1YG0, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
    How can I follow the stock ratings of top Wall Street analysts?
    Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
      Is Immunicum AB a Buy, Sell or Hold?
      Currently, no data Available
      What is Immunicum AB’s share price target?
      Currently, no data Available
      What do analysts say about Immunicum AB?
      Not enough analysts have published a price target to provide an average price target.
      How can I buy shares of Immunicum AB?
      To buy shares of DE:1YG0, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.
        What am I Missing?
        Make informed decisions based on Top Analysts' activity
        Know what industry insiders are buying
        Get actionable alerts from top Wall Street Analysts
        Find out before anyone else which stock is going to shoot up
        Get powerful stock screeners & detailed portfolio analysis